IP Library Granted Patent US 10,548,748
Granted Patent B2
US 10,548,748 · App. 15/840,954 · Granted Feb 4, 2020

Procedures for vascular occlusion

Inventors: Aaron Lee Berez (Portola Valley, CA); Quang Quoc Tran (Atherton, CA)
Assignee: COVIDIEN LP
A61F2/82A61B17/12036A61B17/12109A61B17/12118A61B17/12172A61B17/320758A61F2/01A61F2/06A61F2/852A61F2/90A61F2/95A61M5/007A61M25/00A61M29/00A61B17/12177A61B2017/00336A61B2017/1205A61B2017/12054A61B2017/22079A61B2017/320716A61B2017/320766A61B2017/320791A61B2090/3966A61F2/013A61F2/966A61F2002/011A61F2002/823A61F2002/826A61F2002/9528A61F2230/0078A61F2230/0091A61F2230/0095A61F2250/0018A61F2250/0026A61F2250/0065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,748
App. No.
15/840,954
Granted
Feb 4, 2020
Kind
B2
Abstract

A method of reducing blood flow within an aneurysm includes: injecting a contrast agent into a blood vessel including an aneurysm; expanding a stent, from a delivery device, across the aneurysm; and confirming that a stagnated area forms in the aneurysm. The stagnated area can form a crescent shape, a mushroom shape, a hemispherical shape, and/or a flat side. Upon confirming that the stagnated area forms in the aneurysm, the delivery device can be withdrawn from the blood vessel. The stagnated area can include the contrast agent. If the stagnated area does not form in the aneurysm, a second occluding device may be deployed. After withdrawing the delivery device, substantially all of the aneurysm progressively thromboses.

Claims (39)

1. A method of reducing blood flow within an aneurysm comprising:

injecting a contrast agent into a blood vessel comprising an aneurysm;

deploying an occlusion device from a delivery device in the blood vessel next to the aneurysm;

producing an image of the aneurysm including the contrast agent;

confirming that the contrast agent forms a shape after deploying the occlusion device; and

while the contrast agent has formed the shape, withdrawing the delivery device from the blood vessel.

2. The method of claim 1 , wherein the shape comprises a crescent shape, a mushroom shape, a hemispherical shape, and/or a flat side.

3. The method of claim 1 , wherein the shape formed by the contrast agent comprises a stagnated area in the aneurysm.

4. The method of claim 1 , wherein after withdrawing the delivery device, substantially all of the aneurysm progressively thromboses.

5. The method of claim 1 , wherein the confirming is sufficient to determine that the deploying the occlusion device is sufficient to lead to thrombosis of the aneurysm.

6. The method of claim 1 , wherein the confirming comprises comparing a first image of the aneurysm before deploying the occlusion device to a second image of the aneurysm after deploying the occlusion device.

7. The method of claim 1 , wherein deploying the occlusion device comprises expanding a stent across a neck of the aneurysm.

8. The method of claim 1 , wherein confirming that the contrast agent forms a shape comprises confirming that the contrast agent forms a persistent shape.

9. The method of claim 1 , further comprising observing stagnation within the aneurysm caused by the occlusion device.

10. A method of implanting a stent at an aneurysm comprising:

providing an elongate body comprising a proximal portion, a distal portion, and a lumen extending between the proximal portion and the distal portion;

advancing the elongate body into a patient until the distal portion is adjacent to the aneurysm;

delivering a stent across the aneurysm from within the lumen at the distal portion of the elongate body, wherein delivering the stent comprises expanding the stent from a compressed configuration to an expanded configuration with a first location distal to the aneurysm and a second location proximal to the aneurysm;

observing stagnation within the aneurysm caused by delivering the stent across the aneurysm; and

withdrawing the elongate body from the patient with the expanded stent remaining across the aneurysm once the observed stagnation produces a persistent shape in the aneurysm.

11. The method of claim 10 , wherein the persistent shape comprises a crescent shape, a mushroom shape, a hemispherical shape, and/or a flat side.

12. The method of claim 10 , wherein after withdrawing the elongate body, substantially all of the aneurysm progressively thromboses.

13. The method of claim 10 , wherein observing stagnation within the aneurysm comprises injecting a contrast agent into a blood vessel comprising the aneurysm.

14. The method of claim 13 , wherein observing stagnation within the aneurysm comprises producing an image of the aneurysm including the contrast agent.

15. A method of reducing blood flow within an aneurysm comprising:

injecting a contrast agent into a blood vessel comprising an aneurysm, at least a portion of the contrast agent flowing into the aneurysm;

deploying an occlusion device from a delivery device in the blood vessel next to the aneurysm;

stagnating the portion of the contrast agent in the aneurysm;

producing an image of the aneurysm including the portion of the contrast agent;

observing a shape formed by the portion of the contrast agent in the aneurysm after deploying the occlusion device; and

withdrawing the delivery device from the blood vessel after observing the shape.

16. The method of claim 15 , wherein the shape comprises a crescent shape, a mushroom shape, a hemispherical shape, and/or a flat side.

17. The method of claim 15 , wherein the shape formed by the contrast agent comprises a stagnated area in the aneurysm.

18. The method of claim 15 , wherein after withdrawing the delivery device, substantially all of the aneurysm progressively thromboses.

19. The method of claim 15 , wherein the delivery device comprises a catheter.

20. The method of claim 15 , wherein the observing is sufficient to determine that the deploying the occlusion device is sufficient to lead to thrombosis of the aneurysm.

21. The method of claim 15 , wherein the observing comprises comparing a first image of the aneurysm before deploying the occlusion device to a second image of the aneurysm after deploying the occlusion device.

22. The method of claim 15 , wherein deploying the occlusion device comprises expanding a stent across a neck of the aneurysm.

23. The method of claim 15 , wherein observing a shape formed by the portion of the contrast agent in the aneurysm comprises confirming that the contrast agent forms a persistent shape.

Assignments (5)
MERGER Recorded Oct 9, 2019
From: CHESTNUT MEDICAL TECHNOLOGIES, INC.
To: EV3 INC.
Reel/Frame 050665/0637 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2019
From: EV3 LLC
To: TYCO HEALTHCARE GROUP LP
Reel/Frame 050665/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2019
From: BEREZ, AARON LEE; TRAN, QUANG QUOC
To: CHESTNUT MEDICAL TECHNOLOGIES, INC.
Reel/Frame 050670/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2019
From: TYCO HEALTHCARE GROUP LP
To: COVIDIEN LP
Reel/Frame 050676/0380 →
CHANGE OF NAME Recorded Oct 9, 2019
From: EV3 INC.
To: EV3 LLC
Reel/Frame 051486/0422 →
Continuity (9)
Continuation 15083529 · Mar 29, 2016
Continuation 14791617 · Jul 6, 2015
Continuation 13652591 · Oct 16, 2012
Continuation 12751997 · Mar 31, 2010
Continuation In Part 14885576 · Oct 16, 2015
Continuation 14026510 · Sep 13, 2013
Continuation 12490285 · Jun 23, 2009
Provisional Application 61288525 · Dec 21, 2009
Related Publication 20180147075A1 · May 31, 2018